[Administration of polysaccharide K (PSK) for stage III colorectal cancer in clinical practice].
OBJECTIVE
This retrospective study was performed to evaluate the administration and effect of PSK in patients with stage III colorectal cancer in clinical practice.


METHODS
The subjects were 55 patients with stage III colorectal cancer who received adjuvant chemotherapy, comprising UFT in 44, UFT/calcium folinate (Leucovorin) in 4 and 5-FU/levofolinate calcium (l-LV) in 7, between April 2000 and December 2006. The rate of administering PSK, disease-free survival time, and overall survival time were evaluated.


RESULTS
The rate of administering PSK was 82%. There was no significant difference in disease-free survival and overall survival between patients who received PSK and those without. Among the patients in stage IIIa, the patients who received PSK tended to show a longer overall survival time than those without PSK (p =0.15).


CONCLUSIONS
The rate of administering PSK is high in patients with stage III colorectal cancer. But further cases would be needed to evaluate the effect of PSK with 5-FU-based adjuvant chemotherapy.
Ishibashi
Keiichiro
K
Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
Ishiguro
Toru
T
Kuwabara
Kouki
K
Ohsawa
Tomonori
T
Okada
Norimichi
N
Miyazaki
Tatsuya
T
Yokoyama
Masaru
M
Matsuki
Moriyuki
M
Ishida
Hideyuki
H
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011134:Polysaccharides / Q000008:administration & dosage* / Q000627:therapeutic use*; D015996:Survival Rate
D000970:Antineoplastic Agents; D011134:Polysaccharides